Modality
Small Molecule
MOA
PCSK9i
Target
C5
Pathway
Apoptosis
Endometrial Ca
Development Pipeline
Preclinical
~Jun 2017
→ ~Sep 2018
Phase 1
~Dec 2018
→ ~Mar 2020
Phase 2
Jun 2020
→ Feb 2027
Phase 2Current
NCT05575955
873 pts·Endometrial Ca
2020-11→TBD·Recruiting
NCT08654436
758 pts·Endometrial Ca
2020-06→2027-02·Terminated
1,631 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-02-0210mo awayPh2 Data· Endometrial Ca
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
P2
Termina…
P2
Recruit…
Catalysts
Ph2 Data
2027-02-02 · 10mo away
Endometrial Ca
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05575955 | Phase 2 | Endometrial Ca | Recruiting | 873 | ACR20 |
| NCT08654436 | Phase 2 | Endometrial Ca | Terminated | 758 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| ARG-1250 | Argenx | Phase 2 | C5 |